Clinical trials: Diffuse Parenchymal Lung Diseases
Pneumoconiosis
Efficacy and Safety of Pirfenidone Capsules in the Treatment of Pneumoconiosis
This study is a randomized, double-blind, placebo-controlled, multicenter clinical study. The main purpose of this study was to confirm the efficacy and safety of pirfenidone capsules in the treatment of pneumoconiosis.
- Trial name
- NCT05288179
- Testing
- Pirfenidone Capsules
- Where
- China
- Volunteers
- 272 people
- Sponsor
- Beijing Continent Pharmaceutical Co, Ltd.
Systemic Sclerosis, Scleroderma
Study to Compare the Efficacy of Mycophenolate Mofetil in Systemic Sclerosis Related Early Interstitial Lung Disease
Systemic sclerosis is a multisystem disease and can involve the lungs in the form of ILD. Lung involvement is the most common cause of death in these patients.
- Conditions
- Systemic Sclerosis, Scleroderma, Interstitial Lung Disease
- Trial name
- MYILD (NCT02896205)
- Testing
- Mycophenolate mofetil
- Where
- India
- Volunteers
- 41 people
- Sponsor
- Post Graduate Institute of Medical Education and Research, Chandigarh
Acute Respiratory Failure, Pulmonary Fibrosis
RENOVATE Fibrosis:HFNC Versus NIPPV in Acute Respiratory Failure in Patients With Pulmonary Fibrosis
A pilot multicentric randomized controlled study investigating the feasibility of recruiting 50 pulmonary fibrosis patients in acute respiratory failure within18 months.
- Trial name
- Fibrosis (NCT04253405)
- Testing
- High Flow Nasal Catheter, Noninvasive positive pressure ventilation (NIPPV)
- Where
- 6 sites in Brazil
- Volunteers
- 3 people
- Sponsor
- Hospital do Coracao
Interstitial Lung Disease
Evaluation of the Reproducibility of the Automated Measurement of the Extent of ILD on Chest CT
In interstitial lung disease (ILD), the extent of ILD on chest computed tomography (CT) is recognized as an important prognostic factor.
- Trial name
- REPRO-PID (NCT06743022)
- Testing
- Chest CT
- Where
- 6 sites in France
- Volunteers
- 150 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Idiopathic Pulmonary Fibrosis
First Time in Human (FTIH) Study of GSK3008348 in Healthy Volunteers and Idiopathic Pulmonary Fibrosis Patients
GSK3008348 is an investigational drug, being developed by GlaxoSmithKline Research and Development Limited (the Sponsor, a pharmaceutical company based in the UK) for the treatment of Idiopathic Pulmonary Fibrosis (IPF).
- Trial name
- NCT02612051
- Testing
- GSK3008348 Nebuliser solution, GSK26346763: ([18F]-FBA-A20FMDV2) IV infusion
- Where
- United Kingdom
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Drug Induced Interstitial Lung Disease (DIILD) Cancer Patients
Imaging Biomarker in Cancer Drug Induced ILD
Drug induced interstitial lung disease (DIILD) is caused by iatrogenic injury to the lung parenchyma and can be caused by over four hundred different drugs in humans.
- Trial name
- ImageILD (NCT03294746)
- Testing
- Clinical evaluations, Thoracic CT
- Volunteers
- 70 people
- Sponsor
- European Organisation for Research and Treatment of Cancer - EORTC
Chronic Obstructive Pulmonary Disease, Interstitial Lung Disease
Lung Tissue Research Consortium
The LTRC will facilitate histopathological research of pulmonary diseases by collecting lung tissues from donors and preparing and distributing collections of tissue specimens to researchers within and outside the LTRC.
- Trial name
- LTRC (NCT02988388)
- Testing
- Lung biopsy/lobectomy
- Where
- 4 sites in United States
- Volunteers
- 247 people, healthy volunteers welcome
- Sponsor
- National Heart, Lung, and Blood Institute (NHLBI)
Idiopathic Pulmonary Fibrosis
Garadacimab Safety, Pharmacokinetics, and Pharmacodynamics in Idiopathic Pulmonary Fibrosis
This is a prospective, phase 2a, multicenter, randomized, double-blind, placebo-controlled, parallel-group study to assess the safety, pharmacokinetics (PK), and pharmacodynamics (PD) of garadacimab in subjects with idiopathic…
- Trial name
- NCT05130970
- Testing
- Garadacimab
- Where
- 47 sites in United States, Australia and 9 more
- Volunteers
- 81 people
- Sponsor
- CSL Behring
Idiopathic Pulmonary Fibrosis
The Safety, Tolerability and Pharmacokinetic Study of HEC585 in Healthy Male and Female Subjects
The Safety, Tolerability and Pharmacokinetic Study of idiopathic pulmonary fibrosis treatment drug HEC585 in Healthy Male and Female Subjects
- Trial name
- NCT03092102
- Testing
- HEC585
- Where
- United States
- Volunteers
- 136 people, healthy volunteers welcome
- Sponsor
- Sunshine Lake Pharma Co., Ltd.
Pneumoconiosis
The Experience of Patients and Family Caregivers in Managing Pneumoconiosis in the Family Context
This is an exploratory qualitative study to understand the needs of patients with pneumoconiosis, and the care-giving experience of their family caregivers.
- Trial name
- NCT04022902
- Testing
- No intervention
- Where
- Hong Kong
- Volunteers
- 83 people
- Sponsor
- Chinese University of Hong Kong
Pulmonary Fibrosis
Head-to-head Comparison of Diagnosis Value of Pulmonary Fibrosis on 68Ga-FAPI-04 and 18F-FDG PET-CT
68Ga-fibroblast activating protein inhibitors(FAPI) has been developed as a tumor-targeting agent as fibroblast activation protein is overexpressed in cancer-associated fibroblasts and some inflammation,such as inflammatory bowel…
- Trial name
- NCT05121779
- Testing
- 68Ga-FAPI, 18F-FDG
- Where
- China
- Volunteers
- 80 people
- Sponsor
- Peking Union Medical College Hospital
Interstitial Lung Disease
Hyperpolarized 129Xe MRI for Imaging Pulmonary Function
The purpose of this study is to develop and evaluate the usefulness of MRI using 129Xe gas for regional assessment of pulmonary function.
- Trial name
- NCT01280994
- Testing
- Hyperpolarized 129Xenon Gas
- Where
- United States
- Volunteers
- 445 people, healthy volunteers welcome
- Sponsor
- Bastiaan Driehuys
Idiopathic Pulmonary Fibrosis, Acute Exacerbation of Idiopathic Pulmonary Fibrosis
Intravenous Immunoglobulin for the Treatment of Acute Exacerbations of Idiopathic Pulmonary Fibrosis
Acute exacerbations of idiopathic pulmonary fibrosis (AE-IPF) are sudden and severe worsening episodes that can be life-threatening. Currently, no treatment has been proven to clearly improve outcomes during these events.
- Trial name
- MERCURION-IPF (NCT07299695)
- Testing
- Intravenous immunoglobulin (IVIG), Usual treatment
- Where
- Greece
- Volunteers
- 196 people
- Sponsor
- Argyrios Tzouvelekis
Pulmonary Fibrosis, Lung Cancer
Preliminary Evaluation of [68Ga]CBP8 in Healthy Individuals, Lung Cancer, and Idiopathic Pulmonary Fibrosis Patients
The goal of this study is to investigate the safety of [68Ga]CBP8 and its efficacy to detect collagen deposition in pulmonary fibrosis.
- Trial name
- NCT03535545
- Testing
- [68Ga]CBP8, PET Imaging
- Where
- United States
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- Massachusetts General Hospital
Lung Diseases, Interstitial
Database for Interstitial Lung Disease
The purpose of this study is to establish a clinical database for patients bearing at risk for ILD (Interstitial Lung Disease) and to set up a prospective ILD Screening program for these patients.
- Trial name
- NCT04707781
- Testing
- chest CT
- Where
- Austria
- Volunteers
- 412 people
- Sponsor
- Medical University of Graz
Sarcoidosis, Uveitis
Eye and Immunogenetic Features of Sarcoidosis
This study will evaluate patients with sarcoidosis to understand how the disease affects the body. Sarcoidosis is a disease that results from inflammation of body tissues.
- Trial name
- NCT00379275
- Where
- United States
- Volunteers
- 100 people
- Sponsor
- National Eye Institute (NEI)
Idiopathic Pulmonary Fibrosis, Interstitial Lung Disease
The Edinburgh Lung Fibrosis Molecular Endotyping (ELFMEN) Study
To prospectively study novel blood and lung biomarkers of disease activity in patients with IPF and other interstitial lung disease with the aims of prognostic modelling and disease clustering
- Conditions
- Idiopathic Pulmonary Fibrosis, Interstitial Lung Disease, Asbestosis
- Trial name
- ELFMEN (NCT04016181)
- Volunteers
- 800 people
- Sponsor
- University of Edinburgh
Graft Dysfunction, Interstitial Fibrosis
Novartis Everolimus Transition
Transition from tacrolimus based triple therapy with Mycophenolate Mofetil (MMF) and steroids in stable renal transplant patients to low intensity tacrolimus, everolimus and prednisone will be associated with improvement in…
- Trial name
- NCT02096107
- Testing
- Everolimus, Standard of Care
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- Medical University of South Carolina
Idiopathic Pulmonary Fibrosis, Lung Transplant; Complications
Pirfenidone as Bridging Therapy for Lung Transplant in Patients Suffering From Idiopathic Pulmonary Fibrosis
The diagnosis of idiopathic pulmonary fibrosis (IPF) is currently one of the most common diagnoses for patients under evaluation for lung transplantation.
- Trial name
- NCT03258801
- Where
- Austria
- Sponsor
- Dr. Christopher Lambers
Langerhans Cell Histiocytosis
Thalidomide, Cyclophosphamide and Dexamethasone for Recurrent/Refractory Adult Langerhans Cell Histiocytosis
Langerhans cell histiocytosis (LCH) is a rare, heterogeneous histiocytic disorder occurring most commonly in children. Because of the rarity of LCH in adults and a lack of prospective randomized trials, the treatment strategy for…
- Trial name
- NCT04120519
- Testing
- thalidomide combined with dexamethasone and cyclophosphamide
- Where
- China
- Volunteers
- 20 people
- Sponsor
- Peking Union Medical College Hospital
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.